Overview: CD49d Flow TestIntroduction: The CD49d Flow Test measures CD49d expression to assess chronic lymphocytic leukemia prognosis, helping predict disease progression. Aligned with 2023 ASH guidelines, it uses flow cytometry for high specificity, aiding in cancer screening. This test is critical for guiding treatment planning, monitoring disease, and improving outcomes in immunology for patients with suspected leukemia.
Other Names: CD49d Assay, CLL Prognosis Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: CD49d testing began in the 2000s with CLL research. Flow cytometry assays emerged in the 2010s, improving prognostic accuracy for leukemia.
Purpose: Assesses CLL prognosis, guides treatment, and monitors disease progression in patients with suspected leukemia.
Test Parameters: 1. CD49d
Pretest Condition: No fasting required. Collect whole blood or bone marrow at any time. Report symptoms like fatigue or lymphadenopathy, and list medications like chemotherapy.
Specimen: 2-5 mL whole blood (EDTA) or 2-5 mL bone marrow (EDTA). Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fatigue, lymphadenopathy, or family history of leukemia. Include current medications, especially chemotherapy or targeted therapies.
Consent: Written consent required, detailing the tests purpose, prognostic implications, and potential need for leukemia treatment.
Procedural Considerations: Uses flow cytometry to measure CD49d expression. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Improper storage or delayed transport can affect cell viability. Recent chemotherapy may alter results.
Clinical Significance: High CD49d expression indicates aggressive CLL, prompting earlier treatment. Low expression suggests a more favorable prognosis.
Specialist Consultation: Consult a hematologist for result interpretation. An oncologist referral is advised for treatment planning.
Additional Supporting Tests: Flow cytometry panel, ZAP-70 test, or cytogenetic testing to confirm CLL prognosis or assess disease extent.
Test Limitations: Results may vary with sample quality. Clinical correlation with other prognostic markers is required.
References: ASH CLL Guidelines, 2023; Blood, Hallek M, 2022.
